Brainify.AI’s Companion Diagnostics platform is designed for pharmaceutical partners who want to connect the right patients with the therapies that can truly help them. In drug development, companion diagnostics play a key role; they’re the tests that help identify which patients are most likely to benefit from a new treatment.

Our platform takes this a step further by using EEG biomarkers - real, objective signatures from the brain - to sort patients in clinical trials and, later, to guide real-world treatment decisions. There’s no need for specialized hardware; the system works with any standard clinical EEG, making it easy to integrate into existing setups.

What sets Brainify.AI apart is the power of our AI-driven EEG analytics. By analyzing neural patterns, we can help uncover which patients are likely to respond to a drug or might be at risk for side effects. For pharma partners, this means better-targeted trials, higher chances of success, and ultimately, more effective treatments reaching those who need them.

We work directly with pharmaceutical companies through collaboration contracts, supporting both R&D and clinical trials. The goal is always the same: helping new therapies find their perfect match.